Mutations of PIK3CA in anaplastic oligodendrogliomas, high-grade astrocytomas, and medulloblastomas

Daniel K. Broderick, Chunhui Di, Timothy J. Parrett, Yardena R. Samuels, Jordan M. Cummins, Roger E. McLendon, Daniel W. Fults, Victor E Velculescu, Darell D. Bigner, Hai Yan

Research output: Contribution to journalArticle

Abstract

The phosphatidylinositol 3′-kinase pathway is activated in multiple advanced cancers, including glioblastomas, through inactivation of the PTEN tumor suppressor gene. Recently, mutations in PIK3CA, a member of the family of phosphatidylinositol 3′-kinase catalytic subunits, were identified in a significant fraction (25-30%) of colorectal cancers, gastric cancers, and glioblastomas and in a smaller fraction of breast and lung cancers. These mutations were found to cluster into two major "hot spots" located in the helical and catalytic domains. To determine whether PIK3CA is genetically altered in brain tumors, we performed a large-scale mutational analysis of the helical and catalytic domains. A total of 13 mutations of PIK3CA within these specific domains were identified in anaplastic oligodendrogliomas, anaplastic astrocytomas, glioblastoma multiforme, and medulloblastomas, whereas no mutations were identified in ependymomas or low-grade astrocytomas. These observations implicate PIK3CA as an oncogene in a wider spectrum of adult and pediatric brain tumors and suggest that PIK3CA may be a useful diagnostic marker or a therapeutic target in these cancers.

Original languageEnglish (US)
Pages (from-to)5048-5050
Number of pages3
JournalCancer Research
Volume64
Issue number15
DOIs
StatePublished - Aug 1 2004

Fingerprint

Oligodendroglioma
Medulloblastoma
Astrocytoma
Glioblastoma
Phosphatidylinositol 3-Kinase
Catalytic Domain
Mutation
Brain Neoplasms
Stomach Neoplasms
Ependymoma
Tumor Suppressor Genes
Oncogenes
Colorectal Neoplasms
Lung Neoplasms
Neoplasms
Pediatrics
Breast Neoplasms
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Broderick, D. K., Di, C., Parrett, T. J., Samuels, Y. R., Cummins, J. M., McLendon, R. E., ... Yan, H. (2004). Mutations of PIK3CA in anaplastic oligodendrogliomas, high-grade astrocytomas, and medulloblastomas. Cancer Research, 64(15), 5048-5050. https://doi.org/10.1158/0008-5472.CAN-04-1170

Mutations of PIK3CA in anaplastic oligodendrogliomas, high-grade astrocytomas, and medulloblastomas. / Broderick, Daniel K.; Di, Chunhui; Parrett, Timothy J.; Samuels, Yardena R.; Cummins, Jordan M.; McLendon, Roger E.; Fults, Daniel W.; Velculescu, Victor E; Bigner, Darell D.; Yan, Hai.

In: Cancer Research, Vol. 64, No. 15, 01.08.2004, p. 5048-5050.

Research output: Contribution to journalArticle

Broderick, DK, Di, C, Parrett, TJ, Samuels, YR, Cummins, JM, McLendon, RE, Fults, DW, Velculescu, VE, Bigner, DD & Yan, H 2004, 'Mutations of PIK3CA in anaplastic oligodendrogliomas, high-grade astrocytomas, and medulloblastomas', Cancer Research, vol. 64, no. 15, pp. 5048-5050. https://doi.org/10.1158/0008-5472.CAN-04-1170
Broderick DK, Di C, Parrett TJ, Samuels YR, Cummins JM, McLendon RE et al. Mutations of PIK3CA in anaplastic oligodendrogliomas, high-grade astrocytomas, and medulloblastomas. Cancer Research. 2004 Aug 1;64(15):5048-5050. https://doi.org/10.1158/0008-5472.CAN-04-1170
Broderick, Daniel K. ; Di, Chunhui ; Parrett, Timothy J. ; Samuels, Yardena R. ; Cummins, Jordan M. ; McLendon, Roger E. ; Fults, Daniel W. ; Velculescu, Victor E ; Bigner, Darell D. ; Yan, Hai. / Mutations of PIK3CA in anaplastic oligodendrogliomas, high-grade astrocytomas, and medulloblastomas. In: Cancer Research. 2004 ; Vol. 64, No. 15. pp. 5048-5050.
@article{cf948a9f9762404bbb644d3e62f6a0f3,
title = "Mutations of PIK3CA in anaplastic oligodendrogliomas, high-grade astrocytomas, and medulloblastomas",
abstract = "The phosphatidylinositol 3′-kinase pathway is activated in multiple advanced cancers, including glioblastomas, through inactivation of the PTEN tumor suppressor gene. Recently, mutations in PIK3CA, a member of the family of phosphatidylinositol 3′-kinase catalytic subunits, were identified in a significant fraction (25-30{\%}) of colorectal cancers, gastric cancers, and glioblastomas and in a smaller fraction of breast and lung cancers. These mutations were found to cluster into two major {"}hot spots{"} located in the helical and catalytic domains. To determine whether PIK3CA is genetically altered in brain tumors, we performed a large-scale mutational analysis of the helical and catalytic domains. A total of 13 mutations of PIK3CA within these specific domains were identified in anaplastic oligodendrogliomas, anaplastic astrocytomas, glioblastoma multiforme, and medulloblastomas, whereas no mutations were identified in ependymomas or low-grade astrocytomas. These observations implicate PIK3CA as an oncogene in a wider spectrum of adult and pediatric brain tumors and suggest that PIK3CA may be a useful diagnostic marker or a therapeutic target in these cancers.",
author = "Broderick, {Daniel K.} and Chunhui Di and Parrett, {Timothy J.} and Samuels, {Yardena R.} and Cummins, {Jordan M.} and McLendon, {Roger E.} and Fults, {Daniel W.} and Velculescu, {Victor E} and Bigner, {Darell D.} and Hai Yan",
year = "2004",
month = "8",
day = "1",
doi = "10.1158/0008-5472.CAN-04-1170",
language = "English (US)",
volume = "64",
pages = "5048--5050",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "15",

}

TY - JOUR

T1 - Mutations of PIK3CA in anaplastic oligodendrogliomas, high-grade astrocytomas, and medulloblastomas

AU - Broderick, Daniel K.

AU - Di, Chunhui

AU - Parrett, Timothy J.

AU - Samuels, Yardena R.

AU - Cummins, Jordan M.

AU - McLendon, Roger E.

AU - Fults, Daniel W.

AU - Velculescu, Victor E

AU - Bigner, Darell D.

AU - Yan, Hai

PY - 2004/8/1

Y1 - 2004/8/1

N2 - The phosphatidylinositol 3′-kinase pathway is activated in multiple advanced cancers, including glioblastomas, through inactivation of the PTEN tumor suppressor gene. Recently, mutations in PIK3CA, a member of the family of phosphatidylinositol 3′-kinase catalytic subunits, were identified in a significant fraction (25-30%) of colorectal cancers, gastric cancers, and glioblastomas and in a smaller fraction of breast and lung cancers. These mutations were found to cluster into two major "hot spots" located in the helical and catalytic domains. To determine whether PIK3CA is genetically altered in brain tumors, we performed a large-scale mutational analysis of the helical and catalytic domains. A total of 13 mutations of PIK3CA within these specific domains were identified in anaplastic oligodendrogliomas, anaplastic astrocytomas, glioblastoma multiforme, and medulloblastomas, whereas no mutations were identified in ependymomas or low-grade astrocytomas. These observations implicate PIK3CA as an oncogene in a wider spectrum of adult and pediatric brain tumors and suggest that PIK3CA may be a useful diagnostic marker or a therapeutic target in these cancers.

AB - The phosphatidylinositol 3′-kinase pathway is activated in multiple advanced cancers, including glioblastomas, through inactivation of the PTEN tumor suppressor gene. Recently, mutations in PIK3CA, a member of the family of phosphatidylinositol 3′-kinase catalytic subunits, were identified in a significant fraction (25-30%) of colorectal cancers, gastric cancers, and glioblastomas and in a smaller fraction of breast and lung cancers. These mutations were found to cluster into two major "hot spots" located in the helical and catalytic domains. To determine whether PIK3CA is genetically altered in brain tumors, we performed a large-scale mutational analysis of the helical and catalytic domains. A total of 13 mutations of PIK3CA within these specific domains were identified in anaplastic oligodendrogliomas, anaplastic astrocytomas, glioblastoma multiforme, and medulloblastomas, whereas no mutations were identified in ependymomas or low-grade astrocytomas. These observations implicate PIK3CA as an oncogene in a wider spectrum of adult and pediatric brain tumors and suggest that PIK3CA may be a useful diagnostic marker or a therapeutic target in these cancers.

UR - http://www.scopus.com/inward/record.url?scp=3442878125&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3442878125&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-04-1170

DO - 10.1158/0008-5472.CAN-04-1170

M3 - Article

C2 - 15289301

AN - SCOPUS:3442878125

VL - 64

SP - 5048

EP - 5050

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 15

ER -